The gut microbiome, the vast ecosystem of bacteria that live within our digestive system, is becoming increasingly recognised for its essential role in supporting our physical and mental health.
Now, two new studies from the US are showing that the composition of a patient’s gut bacteria could determine how likely they are to respond to cancer therapy.
One study (Gopalakrishnan et al) suggests that melanoma patients who responded to cancer immunotherapies had a more diverse gut microbiome which gave them greater immunity against tumours. Another paper (Routy et al) suggests antibiotics may strip the gut of bacteria that is essential for patients fighting advanced epithelial tumours.
Dr Samuel Forster, a researcher in Hudson Institute’s Centre for Innate Immunity and Infectious Diseases and the Wellcome Trust Sanger Institute in Cambridge, UK explains the findings – and whether we could prime our gut microbiome to help fight cancer.
Can you explain these results of the two studies?
Between 100 and 1000 bacterial species live within our guts and contribute to our health and wellbeing. We all carry at least three times as many bacteria in our guts than cells in our bodies, but scientists are only beginning to understand the important health effects these bacteria may be having.
Immunotherapy is revolutionising the treatment of many previously untreatable cancers but some patients don’t respond and some encounter serious side effects. These patients are withdrawn from immunotherapy and miss out on access to potentially lifesaving treatment.
We now think the mixture of bacteria within a person’s gut may determine both the effectiveness of immunotherapy in fighting cancer and how likely it is that they will experience side effects.
How do these results build on our understanding of the microbiome?
While it was previously clear that gut microbiota played an important role in a patient’s response to cancer immunotherapy, these results provide some important insights into how and why this occurs.
Low bacterial diversity in the gut is generally associated with poor health or medical treatments such as antibiotic use. The more species of bacteria found in the gut, the better the chance that a patient will carry beneficial bacteria that enhance the effectiveness of certain treatments.
Most studies in this area have shown a correlation or an association between particular types of gut bacteria and a particular disease, such as cancer.
These two studies are different in that they actually demonstrate in pre-clinical models that particular bacterial communities are having a direct effect, by stimulating the immune system in a way that improves outcomes of cancer treatment. Some types of gut bacteria seem to act like a vaccine adjuvant which boosts the immune system to make the vaccine (or in this case, the cancer treatment) work better.
How important are the results for cancer treatment?
Importantly Routy et al. identify and experimentally validate an individual species of gut bacteria with significant potential for cancer treatment. Patients could potentially be screened for these species of gut bacteria prior to treatment or have the species introduced (for example, through faecal microbiota transplants) as part of their therapy.
Our understanding of gut microbiota is still hampered by the limited number of bacterial species we have grown in the laboratory and genome sequenced. One key aim of our research is to overcome these barriers by growing the bacteria and making them available to researchers all over the world.
We still know comparatively little about the majority of bacteria that live in our guts. While 95 per cent of bacteria don’t have the ability to cause disease, most research focuses on the less than five per cent that do. Much more research is still required to understand how these bacteria might impact upon our health before we can develop therapies for broad application in cancer patients.
What is this going to mean for immunotherapy?
We are already seeing genetic testing being used to choose the most appropriate treatments for patients undergoing cancer therapy.
As our knowledge of gut bacteria increases, you can imagine a day when we will not only test patients, but even optimise the bacterial communities within their guts, to improve the success of cancer immunotherapy and other treatments.
Hudson Institute communications
t: + 61 3 8572 2697